Scenic Biotech Appoints Industry Veteran Ben Machielse to Board of Directors
11 Julio 2024 - 4:00AM
Business Wire
Scenic Biotech, a pioneer in the field of modifier therapies for
severe diseases, today announced the appointment of Ben Machielse
to its board of directors. Ben brings over 25 years of experience
in the biotech industry with proven expertise in leading the
development of therapeutics through clinical evaluation up to
market approval in start-ups and fully integrated companies. Ben
joins the board to replace Sandra Glucksmann, who is stepping down
as an independent board member.
"As Scenic continues on its mission to develop a novel class of
therapeutics for genetic disorders, Ben's extensive experience
across all stages of drug development and for rare disease
indications, including Niemann-Pick Disease, will be instrumental
in our next phase of growth," said Oscar Izeboud, CEO of Scenic
Biotech. "Together with Ben, we are well positioned to
materialize on Scenic’s potential to rebalance health by
neutralizing disease impact with our pipeline of modifier
therapies. On behalf of the company, I would also like to thank
Sandra for her remarkable contributions over the past seven years.
Her dedication has helped transform the company to where we are
today."
"Scenic’s pioneering approach, fueled by its unique Cell-Seq
platform, is opening unprecedented avenues to map previously
unexplored biological pathways and investigate the complexities of
disease biology in genetic disorders," said Ben Machielse, board
member at Scenic Biotech. "I look forward to supporting the
Scenic team in navigating the path from discovery through
therapeutic development, ensuring that their innovative treatments
reach patients in need."
Ben Machielse brings deep experience in guiding life sciences
companies through the development and regulatory approval of new
therapeutics. He served as Chief Executive Officer of Vtesse, a
rare disease company dedicated to developing treatments for
Niemann-Pick Disease, where he built the company, oversaw the
completion of the pivotal study and the subsequent acquisition by
Sucampo Pharmaceuticals in April 2017. Prior to this, Ben served as
Chief Operating Officer of Omthera Pharmaceuticals, where he led
the development and approval of a drug for the treatment of
hypertriglyceridemia. His contributions were instrumental in
Omthera's IPO and eventual acquisition by AstraZeneca. Ben was also
Executive Vice President of Operations at MedImmune, where he spent
11 years leading the global development and operations of
therapeutic antibodies, small molecules, and vaccine products.
Before his tenure at MedImmune, Ben held executive positions in
product development, quality, and operations at Xoma Corporation
and Centocor BV. Currently, he serves as the chairman of the board
at Mosanna Therapeutics and has held board positions at Polyneuron
Pharmaceuticals, Xencor, Tetragenetics, Comet Therapeutics, and
Complexa. Ben holds a Bachelor of Science in Medical Biology and a
Master’s in Biochemistry from the University of Utrecht in the
Netherlands.
About Scenic Biotech
Scenic Biotech is advancing modifier therapy, a radically new
approach to treating genetic disorders. Instead of targeting the
primary disease-causing mutation, modifier therapy seeks to
rebalance health by acting on another function in the genome that
can neutralize the disease impact, leading to a therapeutic effect.
Our robust pipeline, derived from our proprietary Cell-Seq
platform, includes first-in-class small molecule programs that are
either wholly owned or partnered through strategic collaborations
with multinational pharmaceutical leaders. By unlocking new
pathways in the genome, Scenic will develop a range of modifier
therapies to help patients.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240711671692/en/
Scenic Biotech Oscar Izeboud, PhD, CEO Phone: +31 20 7059
990 Email: info@scenicbiotech.com Trophic Communications Eva
Mulder & Desmond James Phone: +31 65 2331 579 Email:
scenic@trophic.eu